This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Helicobacter Pylori Empiric Treatment in Ulcer Bleeding (HETUB)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2009 by Hospital de Sabadell.
Recruitment status was:  Recruiting
Corporacion Parc Tauli
Centro de Investigación Biomédica en Red
Information provided by:
Hospital de Sabadell Identifier:
First received: May 27, 2008
Last updated: July 7, 2009
Last verified: July 2009
The goal of the study is to compare the effectiveness of empirical Helicobacter pylori treatment compared with treatment depending on diagnostic tests for Helicobacter pylori in patients with Upper gastrointestinal bleeding due to peptic ulcer. Main hypothesis is that empirical treatment will reduce the number of patients lost to follow-up thus improving the cure rates of Hp infection.

Condition Intervention Phase
Peptic Ulcer Hemorrhage Other: Empirical Hp eradication Other: Eradication treatment guided by a positive test Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IV Study Comparing Helicobacter Pylori Empiric Eradication With Test-Guided Treatment in Patients With Peptic Ulcer Bleeding

Resource links provided by NLM:

Further study details as provided by Hospital de Sabadell:

Primary Outcome Measures:
  • Helicobacter pylori eradication rate [ Time Frame: two years ]

Secondary Outcome Measures:
  • Economical evaluation through cost-effectivity study of the empiric erradicator Helicobacter pylori treatment. [ Time Frame: two years ]

Estimated Enrollment: 178
Study Start Date: March 2008
Estimated Study Completion Date: May 2010
Estimated Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Empirical eradication treatment
Other: Empirical Hp eradication
Empirical Helicobacter pylori treatment initiated immediately after oral intake is resumed
Other Name: Standard Hp eradication treatment
Active Comparator: 2
Eradication treatment according to a diagnostic test (URT, histological test, breath test or serology).
Other: Eradication treatment guided by a positive test
Eradication treatment given if there is at least one positive diagnostic test (URT, histological test, breath test or serology) for Helicobacter pylori.
Other Name: Standard Hp treatment


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients older than 18.
  • Informed Consent signed.
  • Diagnosis of no variceal upper gastrointestinal bleeding secondary to a duodenal ulcer, erosive duodenitis or gastric ulcer.
  • Life expectancy longer than 6 months.
  • Able to attend further clinical controls.
  • Absence of the following exclusion criteria.

Exclusion Criteria:

  • Previous eradication treatment.
  • Use of antibiotics 2 weeks prior to inclusion.
  • Need for Antisecretor treatment that cannot be stopped to perform the breath test.
  • Pregnancy or breastfeeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00687336

Contact: Pilar Garcia, Dra. 34-93-723-1010 ext 20101
Contact: Xavier Calvet, Dr. 34-93-723-1010 ext 20101

Hospital de Sabadell, Institut Universitari Parc Tauli Recruiting
Sabadell, Barcelona, Spain, 08208
Sponsors and Collaborators
Hospital de Sabadell
Corporacion Parc Tauli
Centro de Investigación Biomédica en Red
Principal Investigator: Pilar Garcia, Dra. Hospital de Sabadell
Study Chair: Xavier Calvet, Dr. Hospital de Sabadell
  More Information


Responsible Party: Dr. Xavier Calvet Calvo, Hospital de Sabadell Identifier: NCT00687336     History of Changes
Other Study ID Numbers: CIR2007/058
Study First Received: May 27, 2008
Last Updated: July 7, 2009

Keywords provided by Hospital de Sabadell:
Helicobacter pylori
Upper gastrointestinal bleeding

Additional relevant MeSH terms:
Peptic Ulcer
Peptic Ulcer Hemorrhage
Pathologic Processes
Duodenal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases
Gastrointestinal Hemorrhage processed this record on September 19, 2017